Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you're thinking about a three-month supply of weight loss injections, the most important thing to know upfront is this: in the UK, Mounjaro and Wegovy are prescription-only medicines, so every supply — whether for one month or three — requires a clinical assessment from a registered prescriber before a single pen can be dispensed. That said, three months is a meaningful milestone in treatment, and understanding what that period actually looks like in practice is genuinely useful before you begin. The starting dose for both licensed injectables is a low tolerability dose, not the therapeutic level you'll eventually reach, and the first twelve or so weeks of treatment are largely about your body adjusting while your prescriber reviews progress before each repeat supply.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
You inject once a week, same day each week, same general area of skin (abdomen, thigh or upper arm, rotated each time). The first four weeks are the starter phase. For Mounjaro this is 2.5 mg; for Wegovy it begins at 0.25 mg. These doses exist to settle your digestive system rather than to produce rapid weight loss, which is why many people notice modest results in the opening weeks and more noticeable change later. Nausea, some stomach discomfort and fatigue are the most commonly reported early experiences, and they tend to ease as your body adjusts. Before your second pen can be issued, a prescriber reviews how you've responded, this is not a formality but a genuine clinical check, and it determines whether your dose increases or stays the same.
By week eight or nine of treatment (roughly your third pen) many people are at an intermediate dose level. The licensed weight loss injections available in the UK are designed around this gradual escalation precisely because the clinical trial data showed better tolerability with slow titration. You can read more about how the first month of treatment tends to go on our first-month weight loss injection guide.
One practical checking habit worth building right away: each week before you inject, open your fridge and check that your next pen is still sitting between 2 and 8°C and hasn't been accidentally pushed against the freezer compartment. Frozen pens cannot be used. Takes about ten seconds.
Three months is roughly the point at which many people are approaching or just reaching a maintenance-level dose for the first time, depending on how their titration has gone. It is also often when weight loss begins to feel more consistent week on week. The SURMOUNT-1 trial, published in the New England Journal of Medicine, followed participants for 72 weeks, and the average reductions of around 20–21% at the highest tirzepatide dose accumulated over that full period. At the twelve-week mark, participants were typically still mid-titration.
This matters because expectations around a three-month supply can be shaped by marketing rather than evidence. Some people see striking changes early; others find the first quarter is mostly about tolerability and gradual adjustment. Both are clinically normal. If you want context on what the broader evidence base says about how these treatments perform over time, the NICE appraisal of tirzepatide (TA1026) discusses the trial programme in detail.
It's also worth understanding that a three-month period of injections is not a fixed package that you purchase upfront. Each monthly repeat is clinically reviewed independently, that structure exists because your prescriber needs to see how you're tolerating the current dose and whether it's appropriate to increase. Any supplier offering three months of a prescription medicine as a bundled order without individual reassessment is not following safe dispensing practice. Our guide to weight loss injection suppliers covers what to look for when assessing a legitimate UK source.
Most people will move through at least two dose levels in their first twelve weeks, and some will reach three. The prescriber decides this, not the patient, and the decision is based on your reported side effects, your weight trajectory and whether the current dose is well tolerated. You should not alter the timing of dose changes yourself, the Patient Information Leaflet and your prescriber are the right reference points for that, not online forums or general content like this page.
Practically speaking, this means the pens you receive across three months are unlikely to be identical. Your second or third supply may be a different strength. Planning storage accordingly is sensible, if you're likely to have more than one pen in the fridge at once (for instance, a current pen with doses remaining alongside a new supply), keep them clearly labelled by strength. A sharps container for used needles is a practical addition to your kit from week one; used pens and needles cannot go into household recycling.
The broader treatment page at weight loss treatments sets out the full picture of what a private prescription route involves, including the clinical review process that runs before each repeat. For people who want to understand whether their GP might be able to support them on the NHS instead, our page on getting weight loss injections through a GP explains the current phased rollout and eligibility criteria. If cost across multiple months is a factor, weight loss injection costs in the UK gives an honest overview of what private treatment typically involves.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.